New study tracks psoriasis Drug's Real-World impact on diverse skin types

NCT ID NCT07370766

Recruiting now Knowledge-focused Sponsor: Chronicle Academy Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 80 adults in Canada with moderate-to-severe psoriasis who are starting the drug tildrakizumab. Researchers want to see how the treatment affects quality of life and skin clearing over one year, especially in people with darker skin tones (Fitzpatrick type III and above). The goal is to understand how well the drug works in real-world settings and to make sure treatment benefits everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE TO SEVERE PSORIASIS PSORIASIS (PSO)

Contacts and locations

Show contact details

Locations

Burlington Skin and Wellness
RECRUITING

Burlington, Ontario, L7L 3E5, Canada
Centricity Research London Victoria Multispecialty
RECRUITING

London, Ontario, N6A 2C2, Canada
Factor Dermatology
RECRUITING

Ottawa, Ontario, K2A 3Z3, Canada
Locke Dermatology
RECRUITING

Hamilton, Ontario, L8P 4B4, Canada
Panorama Dermatology Clinic
RECRUITING

Kanata, Ontario, K2T 0N7, Canada
Saskatoon Dermatology Centre
RECRUITING

Saskatoon, Saskatchewan, S7T0G3, Canada

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.